The hyper-CVAD regimen in adult acute lymphocytic leukemia

Hematology/Oncology Clinics of North America

Volumn 14, Issue 6, 2000, Pages 1381-1396

  Garcia Manero, Guillermo ^a,b   Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ALPHA INTERFERON; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; FOLINATE CALCIUM; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; LEVOFLOXACIN; MERCAPTOPURINE; MESNA; METHOTREXATE; METHYLPREDNISOLONE; NELARABINE; PREDNISONE; UNCLASSIFIED DRUG; VALACICLOVIR; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ANTIBIOTIC PROPHYLAXIS; BONE MARROW SUPPRESSION; BONE PAIN; BURKITT LYMPHOMA; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; HUMAN; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

EID: 0033638597     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70192-1     Document Type: Article

References (27)

1. Clinical pharmacology of cyclophosphamide
2. The morphological classification of acute lymphoblastic leukaemia: Concordance among observers and clinical correlations
3. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
4. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia
5. Activity of an abl specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemia, including chronic myelogenous leukemia in blast crisis
6. The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies
7. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy
8. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
9. Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response
10. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969
11. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
12. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy
13. Cell kinetics in Burkitt lymphoma
14. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia
15. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia
16. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine
17. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
18. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
19. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B study 8811
20. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: A follow-up report
21. Preclinical and phase I and II trials of rituximab
22. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (sIg +) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine
23. Radiotherapy in Burkitt's lymphoma: Conventional or superfractionated regime - Early results
24. Acute lymphoblastic leukemia
25. Acute lymphoblastic leukemia in patients aged 60 years and over: A population-based study of incidence and outcome
26. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia
27. Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin